PRELUDE THERAPEUTICS INC (PRLD)

US74065P1012 - Common Stock

4  -0.28 (-6.54%)

After market: 4 0 (0%)

Unregistered users can only see 4 years or quarters

Examples of complete financials are available for MSFT and AAPL.

Please register or login for additional data.

TTM
(2024-3-31)
2023
(2023-12-31)
2022
(2022-12-31)
2021
(2021-12-31)
2020
(2020-12-31)
Revenue
0.000.000.000.000.00
Operating Expenses
137.51M132.28M123.54M113.74M58.76M
Research and Development
108.97M103.39M92.89M86.78M48.18M
Selling, General, and Administrative Expenses
28.53M28.88M30.65M26.96M10.59M
Operating Income
-137.51M-132.28M-123.54M-113.74M-58.76M
Other Income/Expense
11.97M10.45M8.10M2.04M1.83M
Income Before Taxes
-125.55M-121.83M-115.44M-111.69M-56.93M
Income Tax
N/AN/AN/AN/AN/A
Net Income
-125.55M-121.83M-115.44M-111.69M-56.93M
EBITDA
-136.20M-131.11M-122.22M-112.82M-58.22M
 
Per Share Data
EPS Diluted Total Ops
-1.88-2.02-2.44-2.43-4.56
Non GAAP EPS
-1.87-2.03-2.44-2.42N/A
 
Statistics

All data in USD

Charts